Grimes & Company Inc. decreased its stake in Pfizer, Inc. (NYSE:PFE) by 0.3% during the second quarter, Holdings Channel reports. The institutional investor owned 58,053 shares of the biopharmaceutical company’s stock after selling 174 shares during the period. Grimes & Company Inc.’s holdings in Pfizer were worth $1,950,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in PFE. D Orazio & Associates Inc. increased its stake in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares in the last quarter. Northstar Group Inc. increased its stake in shares of Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 35 shares in the last quarter. Stone House Investment Management LLC increased its stake in shares of Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 66 shares in the last quarter. Naples Global Advisors LLC increased its stake in shares of Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock valued at $840,000 after buying an additional 79 shares in the last quarter. Finally, Pure Financial Advisors Inc. increased its stake in shares of Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock valued at $756,000 after buying an additional 84 shares in the last quarter. 69.98% of the stock is currently owned by institutional investors.

Pfizer, Inc. (NYSE PFE) opened at 33.00 on Friday. The stock has a market capitalization of $196.94 billion, a price-to-earnings ratio of 27.78 and a beta of 1.01. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $37.39. The company has a 50-day moving average of $33.32 and a 200-day moving average of $33.25.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.02. The business had revenue of $12.78 billion during the quarter, compared to analyst estimates of $13.09 billion. Pfizer had a net margin of 13.76% and a return on equity of 23.68%. The business’s revenue was down 1.7% on a year-over-year basis. During the same period last year, the business earned $0.67 EPS. Analysts anticipate that Pfizer, Inc. will post $2.55 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.88%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s payout ratio is 108.48%.

WARNING: “Grimes & Company Inc. Has $1.95 Million Stake in Pfizer, Inc. (PFE)” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/07/28/grimes-company-inc-has-1-95-million-stake-in-pfizer-inc-pfe.html.

Several equities research analysts have weighed in on the company. Morgan Stanley reaffirmed a “neutral” rating and set a $35.00 price target (down from $38.00) on shares of Pfizer in a research report on Monday, June 12th. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Jefferies Group LLC reaffirmed a “neutral” rating and set a $34.00 price target on shares of Pfizer in a research report on Friday, June 16th. Citigroup Inc. downgraded Pfizer from a “neutral” rating to a “sell” rating and cut their price target for the stock from $38.00 to $31.00 in a research report on Tuesday, May 16th. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $33.00 price target on shares of Pfizer in a research report on Thursday, April 27th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and ten have assigned a buy rating to the company’s stock. Pfizer has an average rating of “Hold” and an average price target of $37.68.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.